{"schema_version":"secwatch.filing_event.v1","accession":"0001641489-26-000019","form_type":"8-K","ticker":"VTVT","cik":"0001641489","company_name":"vTv Therapeutics Inc.","filed_at":"2026-05-13T20:18:25+00:00","discovered_at":"2026-05-13T20:21:00.286221+00:00","generated_at":"2026-05-13T21:52:35.874391+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"vTv Therapeutics reports Q1 net income of $24.1M on $36.8M license revenue; CATT1 enrollment on track","bullets":["Net income attributable to shareholders of $24.1M ($1.94 basic EPS) vs. net loss of $5.1M a year ago.","Revenue of $36.8M from Newsoara license amendment; $20M upfront plus up to ~$115M milestones.","Cash $98.1M at March 31, 2026, up from $88.9M; company says funds through CATT1 topline readout.","Phase 3 CATT1 trial for cadisegliatin in type 1 diabetes — enrollment on track for completion in Q3 2026.","R&D expenses $9.0M (vs. $2.8M) driven by CATT1 trial investment; G&A $4.6M (vs. $3.7M)."],"urls":{"canonical":"https://secwatch.observer/filing/0001641489-26-000019","json":"https://secwatch.observer/filing/0001641489-26-000019.json","markdown":"https://secwatch.observer/filing/0001641489-26-000019.md","text":"https://secwatch.observer/filing/0001641489-26-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641489/000164148926000019/0001641489-26-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641489/000164148926000019/vtvt-20260513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T21:52:35.874391+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}